Company Overview of GlycoRegImmune, Inc.
GlycoRegImmune, Inc., a biotech company, develops natural killer T (NKT) cells targeted therapies for liver disease, autoimmune disorders, and ischemic reperfusion injury. Its programs include NKT I cell inhibitors and NKT II cell modulators. The company is based in San Diego, California.
General Atomics Court
San Diego, CA 92121
Key Executives for GlycoRegImmune, Inc.
Similar Private Companies By Industry
|Mesoblast, Inc.||United States|
|Medi-Physics, Inc.||United States|
|MesoBio LLC||United States|
|Propagenix Inc.||United States|
|Nucelis Inc.||United States|
Recent Private Companies Transactions
April 2, 2015
To contact GlycoRegImmune, Inc., please visit glycoregimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.